PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
News from 87th European Atherosclerosis Society Congress
26-29 May, Maastricht, The Netherlands

More insights in clinical trials with inclisiran

ORION-2 shows benefit in patients with homozygous familial hypercholesterolaemia with reductions in LDL cholesterol of about 30%. These results provided a basis for the ORION-5 study, a randomised trial in patients with homozygous familial hypercholesterolaemia.

Novel PCSK9 inhibitor LIB003 looks good

This phase 2 trial showed reductions in LDL cholesterol of more than 70% with a 4-week dosing schedule; phase 3 development continues.

Incliseran-EAS-Video

LIB003 Video

Watch Professor Raal discussing ORION-2 »

Watch Dr. Evan Stein's take home messages »

Screening for familial hypercholesterolaemia an urgent priority

Screening for this inherited hypercholesterolaemia can help to prevent early death according to this study of more than 1.7 million patient records.

Read the report here »


Check back for more news from the Congress

Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Did you miss the first set of slides in the
Slide Deck Programme?


First two complementary decks focusing on the main results from FOURIER and ODYSSEY OUTCOMES are available for download

DOWNLOAD THEM NOW »

Register now at www.pcsk9forum.org to access our new slide deck programme.
Questions & Answers

Why are new treatments needed?


Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2019. Please click here to unsubscribe from future mailings.